Chengxiao Zheng

Statistics

Publications

Citations

151

H-Index

Active since

2017

Affiliations

Cellular Biomedicine Group (United States)(Current)

Peking Union Medical College Hospital

Shanghai Cell Therapy Research Institute

Chinese Academy of Medical Sciences & Peking Union Medical College

University of Maryland, Baltimore

Chengxiao Zheng is an author at Cellular Biomedicine Group (United States) specializing in oncology, cancer immunotherapy, and chimeric antigen receptor t-cell therapy.

Publications per year

2017–2025

Publications

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma

Xiaoyan Qu, Gang An, Weiwei Sui et al. · Journal for ImmunoTherapy of Cancer · 2022 · 32 citations · Full text

Medicine, Immunology, Oncology +17

Delivery of adipose-derived mesenchymal stem cells attenuates airway responsiveness and inflammation in a mouse model of ovalbumin-induced asthma.

Ranran Dai, Jia Liu, Songbai Cai et al. · PubMed · 2017 · 22 citations

Life Sciences, Immunology, Pathology +14

Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy.

Aibin Liang, Shiguang Ye, Ping Li et al. · Journal of Clinical Oncology · 2021 · 22 citations

Life Sciences, Immunology, Oncology +17

An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

Gang An, Weiwei Sui, Tingyu Wang et al. · Blood · 2020 · 21 citations

Medicine, Hematology, Oncology +16

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Ping Li, Wenjuan Yu, Lili Zhou et al. · Blood · 2023 · 20 citations

Medicine, Hematology, Oncology +16

1–5 of 7